- Notification that Quarterly Report will be submitted late (NT 10-Q)
17 8월 2010 - 1:32AM
Edgar (US Regulatory)
|
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 12b-25
NOTIFICATION OF LATE
FILING
|
OMB
APPROVAL
|
OMB
Number: 3235-0058
|
Expires: May 31,
2012
|
Estimated average burden hours per
response ... 2.50
|
|
SEC FILE
NUMBER
|
33-55254-42
|
|
CUSIP
NUMBER
|
|
(Check
one):
|
|
o
Form 10-K
o
Form 20-F
o
Form 11-K
x
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
|
|
|
|
|
|
For Period
Ended:
|
June 30,
2010
|
|
|
|
|
|
o
Transition Report on
Form 10-K
|
|
|
|
|
|
o
Transition Report on
Form 20-F
|
|
|
|
|
|
o
Transition Report on
Form 11-K
|
|
|
|
|
|
o
Transition Report on
Form 10-Q
|
|
|
|
|
|
o
Transition Report on
Form N-SAR
|
|
|
|
|
|
For the Transition Period
Ended:
|
|
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be
construed to imply that the Commission has verified any information
contained herein.
|
|
If the notification relates to a portion
of the filing checked above, identify the Item(s) to which the notification
relates:
PART I — REGISTRANT
INFORMATION
Neuro
– Biotech Corp.
Full Name of
Registrant
M45 Mining Resources,
Inc.
Former Name if
Applicable
Aeschenvorstadt
71, CH-4051
Address of Principal Executive Office
(Street
and Number)
Basel,
Switzerland
City, State and Zip
Code
PART II — RULES 12b-25(b) AND
(c)
If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks relief pursuant
to Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
x
|
(a)
|
The reasons described in
reasonable detail in Part III of this form could not be eliminated without
unreasonable effort or
expense;
|
x
|
(b)
|
The subject annual report,
semi-annual report, transition report on Form 10-K, Form 20-F,11-K or Form
N-SAR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due date;
and
|
|
|
|
o
|
(c)
|
The accountant's statement or
other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
PART III — NARRATIVE
State below in reasonable detail the
reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, or the transition report
portion thereof, could not be filed within the prescribed time
period.
Our
quarterly report on form 10-Q could not be filed because the accountant requires
additional time to compile and verify the data required to be included in the
report.
SEC 1344
(03-05)
|
|
Persons who are to respond to the
collection of information contained in this form are not required to
respond unless the form displays a currently valid OMB control
number.
|
(Attach extra Sheets if
Needed)
PART IV — OTHER
INFORMATION
(1)
|
|
Name and telephone number of
person to contact in regard to this notification
|
|
|
|
|
|
Barry
Somervail
|
|
41
|
|
61
500 05 16
|
(Name)
|
|
(Area Code)
|
|
(Telephone
Number)
|
|
|
|
|
|
|
|
(2)
|
|
Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of
1934 or Section 30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed? If answer is no, identify
report(s).
|
|
|
Yes
x
No
o
|
|
|
|
(3)
|
|
Is it anticipated that any
significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to
be included in the subject report or portion
thereof?
|
|
|
Yes
o
No
x
|
|
|
|
|
|
If so, attach an explanation of
the anticipated change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
|
|
|
|
Neuro-Biotech Corp.
(Name of Registrant as Specified
in Charter)
has caused this notification to be
signed on its behalf by the undersigned hereunto duly
authorized.
Date:
|
|
August 16,
2010
|
|
By:
|
|
/s/ Barry
Somervail
|
|
|
|
|
|
|
Barry
Somervail
|
|
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|
|
Institute of Biomedical ... (PK) (USOTC:MRES)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Institute of Biomedical ... (PK) (USOTC:MRES)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
Institute of Biomedical Research Corporation New (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Neuro-Biotech Corp. Common Stock News Articles